# MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

> **NCT07505303** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Eccogene** · enrollment: 160 (estimated)

## Conditions studied

- Adult Obesity
- Weight Management

## Interventions

- **DRUG:** ECC4703
- **DRUG:** Placebo
- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT07505303
- **Lead sponsor:** Eccogene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-13
- **Primary completion:** 2026-11-20
- **Final completion:** 2026-11-20
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07505303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07505303, "MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07505303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*